The earnings call conveyed a generally positive sentiment with significant achievements like the FDA approval of ZEVASKYN and strong initial demand. Positive reimbursement trends and financial stability further support a positive outlook. However, logistical challenges in patient treatment and manufacturing scale-up present areas for improvement.

Company Guidance

During Abeona Therapeutics' second-quarter 2025 conference call, significant progress was highlighted with the approval and launch of ZEVASKYN, the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has identified approximately 50 patients for treatment, with plans to treat 10 to 14 patients in 2025. Two qualified treatment centers (QTCs) are operational, and more are planned to ease patient access. The manufacturing capacity is set to increase to treat 10 patients per month by mid-2026. Successful insurance coverage and prior authorization approvals, including a milestone agreement with UnitedHealthcare, support the therapy's market access. Abeona reported a net income of $108.8 million for the second quarter, supported by the sale of a Priority Review Voucher, with cash resources providing over two years of operating capital. Financial guidance will focus on commercialization progress as the company transitions into a revenue-generating phase.

FDA Approval of ZEVASKYN

ZEVASKYN was approved by the FDA in April 2025, marking a significant milestone for Abeona Therapeutics. It is the first and only autologous cell-based gene therapy for RDEB, offering meaningful healing for wounds associated with the condition.

Strong Initial Demand for ZEVASKYN

Within the first three months post-approval, over 50 patients have been identified as candidates for ZEVASKYN, with referrals from both QTCs and other centers.

Positive Reimbursement Trends

ZEVASKYN has achieved positive coverage with multiple national and regional payers, including UnitedHealthcare, and enjoys a 100% prior authorization success rate.

Financial Strength and Profitability Outlook

Abeona reported $225.9 million in cash and anticipates achieving company-wide profitability by early 2026, supported by ZEVASKYN sales.

Community Engagement and Positive Patient Feedback

Engagement with the RDEB community has been positive, with patients from clinical trials reporting durable wound healing lasting several years.

Abeona Therapeutics (ABEO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ABEO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	-0.28 / -	-0.63	―	―	―
Aug 14, 2025	2025 (Q2)	-0.39 / 1.71	-0.26	757.69% (+1.97)	―
May 15, 2025	2025 (Q1)	-0.36 / -0.24	-1.16	79.31% (+0.92)	―
Mar 20, 2025	2024 (Q4)	-0.35 / 0.50	-0.59	184.75% (+1.09)	―
Nov 14, 2024	2024 (Q3)	-0.40 / -0.63	-0.48	-31.25% (-0.15)	―
Aug 12, 2024	2024 (Q2)	-0.34 / -0.26	-0.92	71.74% (+0.66)	―
May 15, 2024	2024 (Q1)	-0.51 / -1.16	-0.54	-114.81% (-0.62)	―
Mar 18, 2024	2023 (Q4)	-0.47 / -0.59	-0.064	-821.88% (-0.53)	―
Nov 13, 2023	2023 (Q3)	-0.53 / -0.48	-1.48	67.57% (+1.00)	―
Aug 08, 2023	2023 (Q2)	-0.67 / -0.92	-2.08	55.77% (+1.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ABEO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$6.56	$7.23	+10.21%
May 15, 2025	$5.39	$5.79	+7.42%
Mar 20, 2025	$5.20	$5.14	-1.15%
Nov 14, 2024	$6.10	$5.95	-2.46%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Abeona Therapeutics (ABEO) report earnings?

Abeona Therapeutics (ABEO) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).

What is Abeona Therapeutics (ABEO) earnings time?

Abeona Therapeutics (ABEO) earnings time is at Nov 17, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ABEO EPS forecast?

ABEO EPS forecast for the fiscal quarter 2025 (Q3) is -0.28.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing